Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Outperform” Rating at Wedbush

Wedbush restated their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a report released on Friday morning,RTT News reports. The firm currently has a $23.00 price objective on the stock.

A number of other analysts have also recently weighed in on YMAB. HC Wainwright reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Wednesday, December 11th. Oppenheimer started coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. Finally, Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Y-mAbs Therapeutics has an average rating of “Buy” and an average price target of $20.89.

Y-mAbs Therapeutics Stock Down 6.8 %

YMAB stock opened at $6.89 on Friday. The company has a market cap of $308.60 million, a price-to-earnings ratio of -12.76 and a beta of 0.69. The business has a fifty day simple moving average of $10.47 and a 200-day simple moving average of $12.16. Y-mAbs Therapeutics has a 52 week low of $6.84 and a 52 week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. During the same period last year, the company posted ($0.18) earnings per share. As a group, analysts expect that Y-mAbs Therapeutics will post -0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Y-mAbs Therapeutics during the third quarter worth about $44,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Y-mAbs Therapeutics by 66.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $133,000. SG Americas Securities LLC acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $178,000. Finally, Empire Financial Management Company LLC acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $210,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.